NO812542L - Nye trisubstituerte imidazolderivater, fremgangsmaate til deres fremstilling, farmasoeytiske preparater som inneholder disse samt deres anvendelse - Google Patents

Nye trisubstituerte imidazolderivater, fremgangsmaate til deres fremstilling, farmasoeytiske preparater som inneholder disse samt deres anvendelse

Info

Publication number
NO812542L
NO812542L NO812542A NO812542A NO812542L NO 812542 L NO812542 L NO 812542L NO 812542 A NO812542 A NO 812542A NO 812542 A NO812542 A NO 812542A NO 812542 L NO812542 L NO 812542L
Authority
NO
Norway
Prior art keywords
phenyl
formula
substituted
atoms
pyridyl
Prior art date
Application number
NO812542A
Other languages
English (en)
Norwegian (no)
Inventor
Alfred Sallmann
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO812542L publication Critical patent/NO812542L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
NO812542A 1980-07-25 1981-07-24 Nye trisubstituerte imidazolderivater, fremgangsmaate til deres fremstilling, farmasoeytiske preparater som inneholder disse samt deres anvendelse NO812542L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH571580 1980-07-25

Publications (1)

Publication Number Publication Date
NO812542L true NO812542L (no) 1982-01-26

Family

ID=4298165

Family Applications (1)

Application Number Title Priority Date Filing Date
NO812542A NO812542L (no) 1980-07-25 1981-07-24 Nye trisubstituerte imidazolderivater, fremgangsmaate til deres fremstilling, farmasoeytiske preparater som inneholder disse samt deres anvendelse

Country Status (23)

Country Link
US (1) US4447431A (enExample)
EP (1) EP0045081B1 (enExample)
JP (1) JPS5756466A (enExample)
KR (13) KR850000883B1 (enExample)
AR (1) AR230269A1 (enExample)
AT (1) ATE17349T1 (enExample)
AU (2) AU7340481A (enExample)
CA (1) CA1175431A (enExample)
DD (2) DD201677A5 (enExample)
DE (1) DE3173434D1 (enExample)
DK (1) DK331881A (enExample)
ES (8) ES8301472A1 (enExample)
FI (1) FI812326L (enExample)
GB (1) GB2080805B (enExample)
GR (1) GR75287B (enExample)
IE (1) IE52071B1 (enExample)
IL (1) IL63410A (enExample)
NO (1) NO812542L (enExample)
NZ (1) NZ197828A (enExample)
PL (8) PL135822B1 (enExample)
PT (1) PT73424B (enExample)
SU (8) SU1235454A3 (enExample)
ZA (1) ZA815078B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002613A1 (fr) * 1981-07-20 1983-08-04 Sallmann, Alfred Composes oxazoiques a triple substitution
EP0084756A1 (de) * 1982-01-22 1983-08-03 Ciba-Geigy Ag Trisubstituierte Oxazaverbindungen
FR2633291B1 (fr) * 1988-06-27 1990-09-07 Oreal Derives d'hydroxy-4 isoxazoles, leur procede de preparation et compositions cosmetiques et pharmaceutiques les contenant
US5252322A (en) * 1989-09-22 1993-10-12 The Gillette Company Skin tanning compositions containing imidazoles
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
EP1306377A3 (en) * 1993-11-08 2003-05-07 Smithkline Beecham Corporation Pyridyl-oxazoles and their use as cytokines inhibitors
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
WO1997035856A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
HUP0002842A3 (en) * 1997-04-24 2002-01-28 Ortho Mcneil Pharm Inc Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates
US20020156104A1 (en) 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
JP2002505690A (ja) 1997-06-19 2002-02-19 スミスクライン・ビーチャム・コーポレイション 新規なアリールオキシピリミジン置換イミダゾール化合物
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6251914B1 (en) 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
BR9910621A (pt) * 1998-05-22 2001-01-30 Smithkline Beecham Corp Novos compostos de imidazol 2-alquil substituìdos
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
ES2221426T3 (es) * 1998-08-20 2004-12-16 Smithkline Beecham Corporation Nuevos compuestos de triazol sustituidos.
US6548503B1 (en) * 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
CA2395564A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc Novel compounds
DE60023025T2 (de) 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1263753B1 (en) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
AU2002246855B2 (en) * 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
JP2005504793A (ja) * 2001-09-05 2005-02-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体
JP4361798B2 (ja) * 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｍｄｍ２インヒビターとしてのシス−イミダゾリン
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
EP1620406A2 (en) * 2003-05-08 2006-02-01 Astellas Pharma Inc. 1,2-diarylimidazoles useful as inhibitors of cox
MY145281A (en) * 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
AU2006229995A1 (en) * 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
WO2013049272A2 (en) * 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558645A (en) * 1968-07-08 1971-01-26 Sandoz Ag 2-(4-(4',5-diphenyl - 2 - imidazolyl)-phenoxy) lower aliphatic monocarboxylic acids
CH561202A5 (enExample) * 1971-05-10 1975-04-30 Ciba Geigy Ag
GB1469532A (en) * 1973-06-28 1977-04-06 Dumex Ltd As Imimdazolyl-alkanoic acid derivatives
US4372964A (en) * 1980-10-30 1983-02-08 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-1H-imidazole-2-methanols

Also Published As

Publication number Publication date
KR850002745A (ko) 1985-05-15
SU1138023A3 (ru) 1985-01-30
PL237005A1 (en) 1983-02-28
ES504257A0 (es) 1982-12-01
KR830006230A (ko) 1983-09-20
ZA815078B (en) 1982-07-28
EP0045081A2 (de) 1982-02-03
ES514585A0 (es) 1983-07-01
IL63410A0 (en) 1981-10-30
KR850000888B1 (ko) 1985-06-26
KR850002756A (ko) 1985-05-15
GB2080805B (en) 1984-03-07
KR850002748A (ko) 1985-05-15
ES514579A0 (es) 1983-05-16
KR850000884B1 (ko) 1985-06-26
ES8306122A1 (es) 1983-05-16
EP0045081B1 (de) 1986-01-08
PL232352A1 (enExample) 1982-12-20
ES8306119A1 (es) 1983-05-16
SU1205763A3 (ru) 1986-01-15
PL237001A1 (en) 1983-02-28
KR850000887B1 (ko) 1985-06-26
KR850000890B1 (ko) 1985-06-26
ES8301472A1 (es) 1982-12-01
US4447431A (en) 1984-05-08
KR850002750A (ko) 1985-05-15
PL237000A1 (en) 1983-02-28
ES8306123A1 (es) 1983-05-16
DK331881A (da) 1982-01-26
ES8306121A1 (es) 1983-05-16
KR850000891B1 (ko) 1985-06-26
PL135822B1 (en) 1985-12-31
AR230269A1 (es) 1984-03-01
PT73424A (en) 1981-08-01
JPS5756466A (en) 1982-04-05
ES514583A0 (es) 1983-05-16
KR850002754A (ko) 1985-05-15
PL237002A1 (en) 1983-02-28
ATE17349T1 (de) 1986-01-15
SU1235454A3 (ru) 1986-05-30
KR850002752A (ko) 1985-05-15
ES8306124A1 (es) 1983-05-16
AU5655586A (en) 1986-09-11
KR850002755A (ko) 1985-05-15
KR850000892B1 (ko) 1985-06-26
ES514582A0 (es) 1983-05-16
IE52071B1 (en) 1987-06-10
KR850002746A (ko) 1985-05-15
CA1175431A (en) 1984-10-02
PT73424B (en) 1983-06-20
SU1205764A3 (ru) 1986-01-15
SU1227112A3 (ru) 1986-04-23
AU7340481A (en) 1982-01-28
ES514580A0 (es) 1983-05-16
ES514581A0 (es) 1983-05-16
GB2080805A (en) 1982-02-10
PL237004A1 (en) 1983-02-28
GR75287B (enExample) 1984-07-13
FI812326A7 (fi) 1982-01-26
KR850000911B1 (ko) 1985-06-27
SU1169534A3 (ru) 1985-07-23
IL63410A (en) 1986-04-29
SU1145928A3 (ru) 1985-03-15
NZ197828A (en) 1985-11-08
DE3173434D1 (en) 1986-02-20
KR850002753A (ko) 1985-05-15
KR850002747A (ko) 1985-05-15
KR850000873B1 (ko) 1985-06-22
PL237003A1 (en) 1983-02-28
ES514584A0 (es) 1983-05-16
EP0045081A3 (en) 1982-04-07
ES8306120A1 (es) 1983-05-16
ES8307245A1 (es) 1983-07-01
KR850000886B1 (ko) 1985-06-26
FI812326L (fi) 1982-01-26
KR850000883B1 (ko) 1985-06-26
KR850000889B1 (ko) 1985-06-26
KR850002749A (ko) 1985-05-15
DD202554A5 (de) 1983-09-21
KR850002744A (ko) 1985-05-15
DD201677A5 (de) 1983-08-03
PL236997A1 (en) 1983-01-03
SU1152520A3 (en) 1985-04-23
KR850000885B1 (ko) 1985-06-26
IE811680L (en) 1982-01-25
KR850001064B1 (ko) 1985-07-25

Similar Documents

Publication Publication Date Title
US4447431A (en) Tri-substituted imidazole derivatives, pharmaceutical preparations containing them, and their use
KR900008566B1 (ko) 치환된 바이시클릭 화합물의 제조방법
EP0533837A1 (en) Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
AU778819B2 (en) 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
BRPI0618354A2 (pt) composto ou seu sal farmaceuticamente aceitável, antagonista do receptor-3 de histamina, agonista inverso do receptor-3 de histamina, preventivo ou remédio
US6900232B2 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
JP6319747B2 (ja) 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用
NO862618L (no) Nye pikolinderivater, fremgangsmaate ved fremstilling derav, anvendelse og medikamenter som inneholder dem.
NZ238576A (en) Pyridinone derivatives, preparation and pharmaceutical compositions thereof
US20220241425A1 (en) Small molecule target bromo/acetyl proteins and uses thereof
JP4166991B2 (ja) ピリドピリミジンまたはナフチリジン誘導体
JPH05178840A (ja) ピリミジンの新誘導体、それらの製造法、得られる中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
JPH0471077B2 (enExample)
JP4882744B2 (ja) 止痒剤
US7064207B2 (en) Androgen receptor antagonists
JP2006520780A (ja) アンドロゲン受容体アンタゴニストとしてのキノリンおよびクロメンの６−スルホンアミド誘導体
EP0022578A1 (en) Pharmaceutical compositions containing 3-Amino-pyrazoline derivatives
US4694018A (en) Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
KR100273181B1 (ko) 신규 피리돈 유도체 그의 제조방법 그에 의해 얻어진 신규 중간체, 그의 의약으로서의 용도 및 그를 함유하는 제약 조성물
DE2360550A1 (de) Indenylaethyltetrazole, -sulfonsaeuren und -phosphorsaeuren
JP3637961B2 (ja) 芳香族含窒素六員環化合物
JPH06157543A (ja) 新規のチエノチアジン誘導体、その製造方法並びにその使用方法
NO812790L (no) Nye diaryl-imidazol-forbindelser, fremgangsmaate til deres fremstilling, farmasoeytiske preparater som inneholder disse og deres anvendelse
US3700691A (en) 3,3-disubstituted-3,4-dihydrobenzodioxepins
DK160049B (da) 6-phenethylaminoalkyl-furo-(3,4-c)-pyridin-derivater, og laegemidler indeholdende saadanne forbindelser